Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), currently valued at $809 million, outlined its financial projections and strategic roadmap during its first Analyst and Investor Day today. The biopharmaceutical company, which has demonstrated impressive revenue growth of 30% over the last twelve months, reaffirmed its 2025 revenue guidance, expecting to generate between $260 to $275 million. Looking further ahead, Xeris anticipates a significant increase in revenue, projecting approximately $750 million by 2030 and expecting Recorlev®, its treatment for Cushing’s syndrome, to reach annual net revenues of around $1 billion by 2035. According to InvestingPro analysis, the company’s stock has delivered a remarkable 106% return over the past year.
The company’s CEO, John Shannon, expressed confidence in the firm’s trajectory, emphasizing a strong foundation built through innovation and a commitment to patient care. Xeris has successfully launched multiple products addressing unmet medical needs, with Recorlev® revenue acceleration marking a pivotal growth phase.
Xeris also highlighted its financial strength, which supports self-funding for both near- and long-term growth, attributing this to rapid revenue growth and disciplined capital management. The company, maintaining a healthy current ratio of 1.72 and an impressive gross profit margin of 82%, remains focused on maintaining an adjusted EBITDA positive status going forward. InvestingPro data reveals multiple additional financial health metrics and insights available for subscribers.
In the realm of product development, Xeris is advancing XP-8121, a potential game-changer for millions living with hypothyroidism. The company’s pipeline also includes early-stage programs utilizing its XeriSol® and XeriJect® technology platforms.
The company’s forward-looking statements, provided during the event, are based on assumptions and assessments made in light of Xeris’ experience, historical trends, and expected future developments. While these projections are indicative of Xeris’ optimism, they are inherently subject to risks and uncertainties that could affect actual outcomes.
This news article is based on a press release statement and does not endorse any claims made by Xeris Biopharma Holdings, Inc. The information provided is intended to offer a factual report of the company’s financial outlook and strategic plans as presented during their Analyst and Investor Day. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with strong price momentum scores and additional growth potential. For comprehensive analysis, investors can access the detailed Pro Research Report, available exclusively to subscribers.
In other recent news, Xeris Pharmaceuticals reported a significant 48% year-over-year increase in revenue for the first quarter of 2025, reaching $60.1 million and surpassing the forecast of $57.88 million. Despite this strong revenue performance, the company posted an earnings per share (EPS) of -$0.06, which fell short of the forecasted -$0.05. Key products such as RECORLEV and Gvoke contributed notably to the revenue growth, with RECORLEV revenue up 141% to $25.5 million. In light of these results, Xeris Pharmaceuticals has raised its full-year revenue guidance to between $255 million and $260 million, indicating confidence in continued growth. Additionally, the company has maintained a positive adjusted EBITDA of $4.4 million, reflecting financial health and operational efficiency. Analysts from Piper Sandler and Leerink Partners showed interest in the company’s growth strategy, particularly regarding RECORLEV and the upcoming XP-8121 product. Xeris Pharmaceuticals also announced a strategic partnership with American Regent to commercialize Gvoke VialDx in the U.S., expanding its market reach. These developments underscore the company’s commitment to maintaining a strong market position and expanding its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.